Gaps in access to prescribed diabetes technology are common, often arise from early device failure, and lead to disruptions in diabetes management, new research found.

The top three reasons for the gaps were delays caused by insurer requirements for prior authorization, problems with suppliers in processing requests for refills, and delays in obtaining updated prescriptions from physicians, according to the survey results, presented by endocrinologist Andrew Welch, DO, at the American Diabetes Association 85th Scientific Sessions .

The access problems were associated with higher A1c levels and lower socioeconomic status and were more common among patients who receive 30-day rather than 90-day prescriptions.

“Almost every single day this theme comes up with patients where they have p

See Full Page